Global Orphan Diseases Partnering 2010-2017: Deal trends, players and financials
|出版商||Current Partnering, a division of Wildwood Ventures Limited||商品編碼||297237|
|出版日期||內容資訊||英文 250+ Pages
|全球罕見疾病相關的合作條件·契約 Global Orphan Diseases Partnering 2010-2017: Deal trends, players and financials|
|出版日期: 2017年03月01日||內容資訊: 英文 250+ Pages||
The Global Orphan Diseases Partnering 2010-2017: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the orphan diseases partnering deals and agreements entered into by the worlds leading healthcare companies
Global Orphan Diseases Partnering 2010 to 2017 provides the full collection of Orphan Diseases disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.
Trends in Orphan Diseases partnering deals
Financial deal terms for headline, upfront and royalty by stage of development
Orphan Diseases partnering agreement structure
Orphan Diseases partnering contract documents
Top Orphan Diseases deals by value
Most active Orphan Diseases dealmakers
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Orphan Diseases disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Orphan Diseases deals.
The report presents financial deal terms values for Orphan Diseases deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
The initial chapters of this report provide an orientation of Orphan Diseases dealmaking trends.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in Orphan Diseases dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
Chapter 4 provides a review of the leading Orphan Diseases deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Orphan Diseases dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides comprehensive access to Orphan Diseases deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all Orphan Diseases partnering deals by specific Orphan Diseases target announced since 2010. The chapter is organized by specific Orphan Diseases therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all Orphan Diseases partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Orphan Diseases partnering and dealmaking since 2010.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Orphan Diseases technologies and products.
Global Orphan Diseases Partnering 2010 to 2017 is intended to provide the reader with an in-depth understanding and access to Orphan Diseases trends and structure of deals entered into by leading companies worldwide.
Global Orphan Diseases Partnering 2010 to 2017 includes:
In Global Orphan Diseases Partnering 2010 to 2017, available deals and contracts are listed by:
The Global Orphan Diseases Partnering 2010-2017 report provides comprehensive access to available deals and contract documents for over 100 orphan diseases deals. Analyzing actual contract agreements allows assessment of the following:
Global Orphan Diseases Partnering 2010 to 2017 provides the reader with the following key benefits: